Use in Jey of PTO/SB/17 (08-03) (Form updated to reflect PY 2004 fees effective 10/1/03)

PPP TPANOLITTAL			Complete if Known						
FEE TRANSMITTAL		Application Number				09/246,1	29-Cont. #5810		
for FY 2004		Filing Date				February 8, 1999			
		First Named Inventor				Guo-Lian	ig Yu		
Ettoctiva 10/01/2003, Patent feest are subject to annual revision		Examiner Name				D. Rome	0		
Applicant claims small entity status See 37 CFR 1 27		Art Unit				1647			
TOTAL AMOUNT OF PAYMENT (\$) 0.00						PF141P4		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
METHOD OF PAYMENT (check all that apply)				FEE	CALCUL	ATION (pg	intinuea)		
Charl Credit Money Other None	3 4	DDITI	ONAL	FEES					
x Deposit Account	Large Enuty Small Entity								
Оброзіт Ассоція	Pea	Fee Fee Fee			-	Fee Desc	ะทะอนิดิก		
Number	Code	(\$)	Code	(\$)				Fee Pard	
Account Human Genome Sciences, Inc.	1051	130	2051	65	Surcharge -	_			
The Director is authorized to (oneck all that apply)	1052	50	2052	25	Surcharge -	· late provisi	onal filing tee or cover		
X Charge ree(s) indicated below X Credit any overpayments	1053	130	1053	130	Non-English	i specificatio	л		
Charge any additional tea(s) during the pendency of this	1812	2,520	1812	2,520	For thing a request for ex parte reckamination				
application	1804	920-	1804	920*	Requesting	publication (of SIR phorio		
Charge tes(s) indicated below, except for the thing fee to the above-identified deposis account.	1805	1.840*	1805	1,840*	Examiner ac Requesting	publication (ot SIR atter		
FEE CALCULATION	1257	110	2251	55	Evaluities	TION			
1. BASIC FILING FEE	1252	420	2252	210		tension for reply within first month tension for reply within second month			
Large Entity Small Entity	1253	950	2253	475			n third month		
Fee Fee Fee Fee Paid	1254	1,480	2254	740	Екрепаюн for reply within fourth month				
Code (\$) Code (\$) 1001 770 2001 385 Ustiny tiling tee	1255	2,010	2255	T,005	Extension for reply within tittle month				
1002 340 2002 170 Design thing two	1401	330	2401	165	Notice of Appeal				
1003 530 2003 265 Prant tiling tee	1402	330	2402	165	Filing a brief in support of an appeal				
1004 770 2004 385 Reissise filing tee	1403	290	2403	145	Request for oral hearing				
1005 160 2005 80 Provisional filing tee	1451	1,510	1461	1,510		Petrion to institute a public use proceeding			
SUBTOTAL (1) (\$) 0.00	1452	110	2452	55	Petition to fevive – unavoidable				
	1453	1,330 1,330 <u> </u>	2453 2501	665 645	Petihoruto revive - uriinteriticinal Utility issue tee (or reissue)				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	480	2501	665	-	· · · · · · · · · · · · · · · · · · ·			
Total Claims -20" = x = =	1503	640	2503	240		ธรรฐการรณชาโดย			
Independent -3"	1460	130	1						
Liams ————————————————————————————————————	1807								
Multiple Dependent	1806								
Foo Foe Foe Foe For	1	D							
Code (5) Code (\$)	8021	40	8021	40	nir) vnegora	(seinegora to ieamun semir) vnegora			
1202 18 2202 9 Claims in excess of 20 1201 86 2201 43 (ndependent claims in excess of 3	1809	770	2609	385		Filing a subtrission after time (ejection) (37 CFR 1 129(a))			
1203 290 2203 145 Multiple dependent claim, if not paid	0787	770	2810	385	For each addmonal invention to be examined (37CFR ; 129(b))				
1204 86 2204 43 ** Reissue ingependent claims	1801	770	2801	365	Request for Continued Examination (RCE)				
Over original patent 1205 78 2205 9 ** Reiseue claims in excess of 20	1802	900	1802	900	Request for		noitenime		
and over ordinal bateur	Other	(specify) of a desig				in application			
SUBTOTAL (2) (\$) 000		cad by i		ing Fee	Paid	SUBTO	TAL (3) (5)	0.00	
** or number previously раю, if graater, For Reissues, see apove							· · · · · · · · · · · · · · · · · · ·		
SUBMITTED BY						(Сотрыя	(d applicable))		
Nama (Proi/Type) Lin J. Hyme)		ration No By/Ayant)		414		Тәівұлогін	(301) 251-6015		
Signature 1. King						Date	October 2, 2003	3	
1, 42,				-					

08/12/03 18:84:18

<-OT92U

3013098439 RightFAX

Page 881

TO: Auto-reply fax to 3013098439 COMPANY:

Auto-Reply Facsimile Transmission



TO:

Fax Sender at 3013098439

Fax Information Date Received: Total Pages:

8/12/03 5:59:56 PM [Eastern Daylight Time] 10 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received Cover Page =====>

fal Trans	MISSION
DATE.	Anxies 12, 2003
CLIENT	P\$1+1P4
MĚŠSAGE	E-mainer David Roman
COMPANY	U.S. Patem & Tredemorp Office, Group 1000
FAX	(703) \$73-9507
PHONE.	\705) \$05-40\$0
FROM.	Lutter Charles
PHONE.	(201) 251-6012
Paces (Ib	endus Coar to each coar to ter in
Messac e:	Ploase only the tollowing documents in the fit of hyppication No. 09/246, 29.
	For Transmina
	Assessment With Response Usager 37 C.F.R. 31 310 to Paper No. 28
	Comments of Transmission Under 77 C.F.R. 31 S
	<u> </u>
	전 your rection of the trensmission is in criter, pressed notify this firm infectionally by collect call to -ender as (고대) 5 stu-5790 and send the enginel transmission to us by fatight moders the address police.
	The measurement is intended for the sole use of the individual and obsert to whom it is addressed, and they contain individual to privilegae. Conflected and except from disciplance used applicable for You are hereby dustries that any disciplance, and replicable of the framework of the product of the framework of the product of the pr
	Human Cenomi Sciences, Inc 2418 Met West A-Crise, Mordanie, Maryrado 20036 Tomphore (601) 616-5790 Facultie, (601) 309-8439

FAX TRANSMISSION

DATE:

August 12, 2003

CLIENT

PF141P4

MESSAGE

Examiner David Romeo

Oct-02-03 02:49pm

U.S. Patent & Trademark Office, Group 1600

FAX

(703) 872-9307

PHONE:

COMPANY:

(703) 305-4050

FROM:

Loma Charles

PHONE:

(301) 251-6012

PAGES (Including Cover

10 HARD COPY TO YES

 $|\mathbf{x}| N$

MESSAG E:

Please enter the following documents in the file of Application No. 09/246,129:

3013098439

Fee Transmittal

Amendment With Response Under 37 C.F.R. §1.116 to Paper No. 28

Certificate of Transmission Under 37 C.F.R. §1.8

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (301) 610-5790 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

HUMAN GENOME SCIENCES, INC. 9410 Key West Avenue, Rockville, Maryland 20850 Telephone: (301) 610-5790 Facsimile: (301) 309-8439

PTC/SB/17 (05-03)
Approved for use through 04/30/2003 QMg 0651-0032
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are requ	O 3 Patient and Trademan, Office 0.5. DEPARTMENT OF COMMERCE							
		Complete if Known						
FEE TRANSMITTAL		Appli	ation	Numb	er	09/246,129-Conf. #5810		
for FY 2003		Filing Date				February 8, 1999		
Effective 01/01/2003, Parent toos are subject to admusi revision		First Named Inventor			Guo-Liang Yu			
	Examiner Name					D. Romeo		
Applicant claims small entity status See 37 CFR 1 27	Art Unit					1647		
TOTAL AMOUNT OF PAYMENT (\$) 0 00	Attorney Docket No.				o.	PF141P4	}	
METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)							
Cneck Credit Money Other None X Deposit Account	3. 4	יודוסםי	DNAL	FEES				
Deposii	_	e Entity		Enuty	_			
Account 08-3425	Fee Code	F ee (\$)	Foo	Foe (\$)		Fee Desi	cription	Fee Paid
Deposit	1051	130	2051	65	Surcharde	- rate filing fo	96 or oath	
Account Human Genome Sciences, Inc.				25	_	-	onal filing fee or cover	.}
The Director is heroby authorized to. (check all that apply)	1052	50	2052	23	Shoet.			
Charge rea(s) indicated pelow X Credit any overpayments	1053	730	1058	130	Non-Englis	so specificatio	n	
X Charge any օգգերում fee(s) գերոց me pengency of mis	1812	2,520	7872	2,520	_		рале гезлатультоп	
Charge tec(a) indicated below, except for the filing tec	1804	93Q*	1804	920"	Examiner a	action	ot SIR prior to	
to the above-identified deposit account	1805	1.840*	1805	1,840*	Requesting	g publication (or SIR after	
FEE CALCULATION	1251	110	2251	55		for reply with	n first month	
1. BASIC FILING FEE	1252	410	2252	205	Extension	ior reply with	n second month	
Large Entity Small Entity For Fee I Fee Fee Fee Description Fee Paid	1253	930	2253	469	Extension	KAT r⇔piy with	n third month	
Code (\$) Code (\$)	1254	1,450	2254	725	Extension	tor reply with	A fourth month	
1001 750 2001 \$75 Utility filing tise	1255	1,970	2255	985		or reply with	तंत्राव्या वर्गाते व	
1002 330 2002 165 Design filing fee	1401	320	2401	160	Notice of A		-6	1
7003 520 2003 260 Plant filing tee 1004 750 2004 375 Reissue filing fee	7402 3403	320 280	2402	160 140		er in support o Forat nearung		
1005 160 2005 80 Provisional filing fee	1457	1,510	1451				i Alië use proceeding	
	1452	110	2452	55		revive – unav		
SUBTOTAL (1) (5) 0 00	1453	1,300	2453	650	Pennon to	ievive - unitili	entional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,300	2501	650	Utility issue	fee (or reiss	ur≑)	
Extra Fee from Claims polow Fee Paid	1502	470	2502	295	Desi8u issi	ue fee		
Total Claints -20" = x =	7,503	630	2503	315	Plant (8856			L
independent -3** = x	1460	130	1460	130		the Commis		├
Multiple Dependent =	1807	50	1807	50	_		7 CFR 1 17(q)	
Large Entity Small Entity Feb Fec Foo Fee Foo Fee	1806	180	1806	180			on Disclosure Simi	
Code (\$) Code (\$)	8021	40	8021	40	property (t)	mes numper	ot properties)	<u> </u>
1202 18 2202 9 Claims in excess of 20	1809	750	2809	375	(\$7 CFR 1.		final rejection	
1201 84 2201 42 Independent claims in excess of 3 1203 280 2203 140 Multiple generating craim, if not paid	1810	750	2810	375	For each a	gamonal mvc		
1204 64 2204 42 "Reissue independent clums	7801	750	2801	375		37CFR 1.129 r Continued 8	(D)) Examination (RCE)	
over original patent			1802	900	Request to	г виреалеа а		
1205 18 2205 9 "Reissue claims in excess of 20 and over original patent	Other tee (specify)				un a gesign	application		
SUBTOTAL (2) (\$) 0.00 "or number previously paid, if greater. For Reissuas, see above								0.00
SUBMITTED BY						Complete	(1 аррысаын)	
Name (Prost/Type) Lin J.,Hymel		ration No sylagenti	45	,414		Telephone	(301) 251-6015	
Signature 1 - 1 S-						Days	August 12, 200	3

VIA FAX AUGUST 12, 2003

Docket No.: PF141P4

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Yu et al

Application No.: 09/246,129

Group Art Unit: 1647

Filed: February 8, 1999

Examiner: D. Romeo

For:

Tumor Necrosis Factor-Gamma

AMENDMENT WITH RESPONSE UNDER 37 C.F.R. § 1.116 TO PAPER NO. 28

Mailstop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Advisory Action mailed July 22, 2003, and the telephone interview held with the Examiner August 11, 2003, please consider the following amendments and remarks. Submitted concurrently herewith is a Certificate of fax transmission.

Prior to further examination, Applicants respectfully request entry of the following amendments.

- Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.
- Remarks begin on page 6 of this paper.

Listing of claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-41. (Cancelled)

- 42. (Currently Amended) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) amino acid residue -27 to amino acid residue +147 as set forth in SEQ ID
 NO:2;
 - (b) amino acid residue -26 to amino acid residue +147 as set forth in SEQ ID NO:2;
 - (c) amino acid residue +1 to amino acid residue +147 as set forth in SEQ ID
 NO:2;
 - (d) a full-length polypeptide having the amino acid sequence expressed by the cDNA plasmid contained in ATCC Deposit No. 75927;
 - (e) a full-length polypeptide, excluding the N-terminal methionine residue, having the amino acid sequence expressed by the cDNA plasmid contained in ATCC Deposit No. 75927; and
 - (f) a polypeptide having the amino acid sequence, excluding the signal sequence, expressed by a recombinant cell comprising encoded by the cDNA plasmid contained in ATCC Deposit No. 75927, wherein said amino acid sequence is encoded by the cDNA plasmid contained in ATCC Deposit No. 75927.
- 43. (Previously presented) The isolated polypeptide of claim 42 consisting of amino acid residue -27 to amino acid residue +147 as set forth in SEQ ID NO:2.
- 44. (Previously presented) The isolated polypeptide of claim 42 consisting of amino acid residue -26 to amino acid residue +147 as set forth in SEQ ID NO:2.

Appl'n Serial No.: 09/246,129

- 45. (Previously presented) The isolated polypeptide of claim 42 consisting of amino acid residue +1 to amino acid residue +147 as set forth in SEQ ID NO:2.
- 46. (Previously presented) The isolated polypeptide of claim 42 consisting of a full-length polypeptide having the amino acid sequence expressed by the human cDNA contained in ATCC Deposit No. 75927.
- 47. (Previously presented) The isolated polypeptide of claim 42 consisting of a full-length polypeptide, excluding the N-terminal methionine residue, having the amino acid sequence expressed by the human cDNA contained in ATCC Deposit No. 75927.
- 48. (Previously presented) The isolated polypeptide of claim 42 consisting of a polypeptide having the amino acid sequence expressed by a recombinant cell comprising the human cDNA contained in ATCC Deposit No. 75927.

49-51. (Cancelled)

- 52. (Previously presented) The isolated polypeptide of claim 42 wherein said polypeptide is fused to a heterologous polypeptide.
- 53. (Previously presented) The isolated polypeptide of claim 52 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.
- 54. (Previously presented) A composition comprising the polypeptide of claim 42 and a pharmaceutically acceptable carrier.
- 55. (Previously presented) An isolated polypeptide encoded by a nucleic acid molecule consisting of a polynucleotide sequence selected from the group consisting of:
 - (a) a polynucleotide sequence consisting of at least 30 contiguous nucleotides of nucleotides 783 to 1304 of SEQ ID NO:1; and
 - (b) a polynucleotide sequence consisting of at least 30 contiguous nucleotides of the open reading frame encoded by the cDNA plasmid contained in ATCC Deposit No. 75927.

Appl'n Serial No.: 09/246,129 3 PF141P4

56. (Previously presented) The isolated polypeptide of claim 55 encoded by a polynucleotide which consists of (a).

57-58. (Cancelled)

59. (Previously presented) The isolated polypeptide of claim 55 encoded by a polynucleotide which consists of (b).

60-61. (Cancelled)

- 62. (Previously presented) The isolated polypeptide of claim 55 wherein said polypeptide is fused to a heterologous polypeptide.
- 63. (Previously presented) The isolated polypeptide of claim 62 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.
- (Previously presented) A composition comprising the polypeptide of claim 64. 55 and a pharmaceutically acceptable carrier.
- (Previously presented) An isolated polypeptide consisting of an amino acid 65. sequence selected from the group consisting of:
 - an amino acid sequence consisting of at least 30 contiguous amino acid (a) residues of SEQ ID NO:2; and
 - an amino acid sequence consisting of at least 30 contiguous amino acid (b) residues encoded by the cDNA plasmid contained in ATCC Deposit No. 75927.
- 66. (Previously presented) The isolated polypeptide of claim 65 which consists of (a).
 - 67-68. (Cancelled)
- 69. (Previously presented) The isolated polypeptide of claim 65 which consists of (b).
 - 70-71. (Cancelled)

Appl'n Serial No.: 09/246,129

PF141P4

- Oct-02-03 02:51pm From-HGS INTELLECTUAL
 - 72. (Previously presented) The isolated polypeptide of claim 65 wherein said polypeptide is fused to a heterologous polypeptide.
 - 73. (Previously presented) The isolated polypeptide of claim 72 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.
 - 74. (Previously presented) A composition comprising the polypeptide of claim 65 and a pharmaceutically acceptable carrier.

75-94. (Cancelled)